IRS-ISIAN 2024 | Remission in CRSwNP: A Real-World Perspective
Rhinology
Prof. Eugenio De Corso describes the importance of real-world evidence for understanding the prospects of remission and the emerging evidence of biologic effectiveness for patients with CRSwNP.
Biologics in CRSwNP: Comparative Efficacy and Real-World Effectiveness
Rhinology
Professor Eugenio De Corso discusses indirect comparisons of biologics approved for patients with uncontrolled CRSwNP and emerging real-world effectiveness of biologics for patients with CRSwNP.
EAACI 2024 Emerging Definitions of Clinical Remission and Achieving Clinical Remission With Biologics for Patients With Asthma
Pulmonology
Join Professor Vibeke Backer for a presentation on clinical remission in asthma and achieving remission with biologics for patients with uncontrolled asthma.
ADVENT On Air | Getting to Grips With Atopic Hand and Foot Dermatitis: What Is It, and What Does It Mean for Patients?
Dermatology
This podcast episode looks at the epidemiology, clinical presentation and classification of atopic dermatitis of the hand and feet and the impact it has on patients' quality of life.
ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.
For healthcare professionals in Algeria: Please read the additional Terms of Use.
Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.